Drug use in primary medical institution
s of 4 provinces is wholly opened! Domestic and foreign pharmaceutical companies are fighting for the 130 billion markets.
▍Since February, Tianjin has opened the drug use catalogs of all medical institutions
On the last day of January 2018, the Tianjin Pharmaceutical Purchasing Center issued the “Tianjin Notice on Adjusting the Scope of Online Purchase of Drugs in Primary Medical Institutions”.
Inform all units that from February 1st, the scope of online drug procurement in Tianjin primary medical institutions will be fully linked to the use of drugs in secondary and tertiary hospitals. That is to say, the catalogs of all public medical institutions in Tianjin are unified, and the drug use in primary medical institutions is no longer restricted.
The Tianjin Municipal Government announced data in 2016: In 2014, there were 4,990 medical and health institutions in Tianjin, including 373 hospitals (39 tertiary hospitals, 54 secondary hospitals, 280 primary hospitals, 211 private hospitals), there are 4,419 primary medical institutions and 145 professional public health institutions.
, 4,419 primary medical institutions have completely opened their medications.
▍ Drug use of 4 provinces is wholly opened
In fact, not only in Tianjin, but also in Beijing, Guangdong, Liaoning, the restrictions on the drug use of primary medical institutions were released in the 2017 . On April 8, 2017, Beijing Sunshine Procurement Platform expanded the drug use catalogs of primary medical institutions, and the drug procurement platforms of original primary medical institutions as well as second and third-grade hospitals are combined into one, and their drug uses are completely consistent.
On June 30, the Guangdong Health and Family Planning Commission issued the "Notice on Further Clarifying the Relevant Requirements for the Basic Drug System of Our Province". Since July 1, 2017, no specific requirements were imposed on the number of specifications and the cost ratio of the national essential drugs at all levels of medical institutions.
On August 1, Liaoning Province issued the “Implementation Opinions on Further Reforming and Perfecting the Policy of Drug Production, Circulation and Use”, requiring all levels of medical institutions implement a unified procurement platform and unified procurement catalogue.
In addition, the proportion of non-based medicines used by primary medical institutions in other provinces across the country are gradually increasing. Such as Anhui, Shandong, Sichuan, Zhejiang, etc., the specific documents are not repeated. In general, drug use opening in primary medical institutions and big third-grade hospitals is an inevitable trend, its emergence is just a matter of time, up to the the difference between the financial resources of various provinces.
▍The unification of drug use at all levels of medical institutions, a general trend
It is easy to make this judgment.
State Council issued “Guiding Opinions on Promoting the Construction and Development of Medical Consortiums” in April 2017, which allowed “medical associations to become a community of services, responsibilities, interests, and management” and set the task of “all secondary public hospitals and government-run primary medical institutions are all involved in the medical association”.
After that, the trusteeship of small and medium-sized hospitals by large hospitals is rapidly propelled. Under this circumstance, the unification of the drug use catalogs of all levels of hospitals is an inevitable result.
▍The expanded market of 130 billion, a battleground for pharmaceutical companies
As mentioned above, the uniform documents used by medical institutions at various levels in many provinces are gradually confirming this judgment.
This is a policy dividend. Many foreign pharmaceutical companies, such as Pfizer and Sanofi, have been emphasizing looking for channels from grass roots
for several years and have seen this huge market early.
At present, the operation of grade hospitals is getting harder and harder, and this ultra-billion-dollar market that has gradually surfaced is sure to become a battleground for pharmaceutical companies.